Clinical characteristics of patients with atrial fibrillation treated with direct oral anticoagulants attended in primary care setting

To analyse the clinical characteristics and management of patients with non-valvular atrial fibrillation (NVAF) treated with direct oral anticoagulants (DOAC). Observational, cross-sectional and multicentre study. Autonomous Communities in which the general practitioner can prescribe DOAC (n = 9). T...

Descripción completa

Detalles Bibliográficos
Autores: de la Figuera, Mariano|||0000-0003-2533-2135, Cinza, Sergio, Marín, Nuria, Egocheaga, Isabel, Prieto, Miguel Angel
Tipo de recurso: artículo
Fecha de publicación:2018
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:español
OAI Identifier:oai:ddd.uab.cat:287811
Acceso en línea:https://ddd.uab.cat/record/287811
https://dx.doi.org/urn:doi:10.1016/j.aprim.2017.05.009
Access Level:acceso abierto
Palabra clave:Anticoagulación
Anticoagulantes orales de acción directa
Anticoagulation
Atención primaria
Direct oral anticoagulants
Fibrilación auricular no valvular
Non-valvular atrial fibrillation
Primary care
id ES_4d4b5978f9ce7a9bbd42f5b95f769f1e
oai_identifier_str oai:ddd.uab.cat:287811
network_acronym_str ES
network_name_str España
repository_id_str
spelling Clinical characteristics of patients with atrial fibrillation treated with direct oral anticoagulants attended in primary care settingThe SILVER-AP studyPerfil clínico de pacientes con fibrilación auricular tratados con anticoagulantes orales de acción directa atendidos en atención primariade la Figuera, Mariano|||0000-0003-2533-2135Cinza, SergioMarín, NuriaEgocheaga, IsabelPrieto, Miguel AngelAnticoagulaciónAnticoagulantes orales de acción directaAnticoagulationAtención primariaDirect oral anticoagulantsFibrilación auricular no valvularNon-valvular atrial fibrillationPrimary careTo analyse the clinical characteristics and management of patients with non-valvular atrial fibrillation (NVAF) treated with direct oral anticoagulants (DOAC). Observational, cross-sectional and multicentre study. Autonomous Communities in which the general practitioner can prescribe DOAC (n = 9). The study included a total of 790 patients on chronic treatment with anticoagulants, and on whom therapy was changed, as well as being currently on treatment with DOAC for at least for 3 months. A record was made of the sociodemographic and clinical management date. Mean age was 78.6 ± 8.4 years, and 50.5% of patients were men. Mean CHADS score was 2.6 ± 1.2, mean CHADS-VASc score was 4.3 ± 1.6, and the mean HAS-BLED score was 2.3 ± 1.0. Mean duration of treatment with DOAC was 15.8 ± 12.5 months. Rivaroxaban was the DOAC most frequently prescribed (57.8%), followed by dabigatran (23.7%), and apixaban (18.5%). Of the patients receiving rivaroxaban, 70.2% were taking the dose of 20 mg/daily. Of the patients receiving dabigatran, 41.7% were taking the dose of 150 mg twice daily, and in the case of apixaban, 56.2% were taking the dose of 5 mg twice daily. Satisfaction (ACTS Burdens scale 52.0 ± 7.2 and ACTS Benefits scale 12.1 ± 2.2), and therapeutic adherence (97.8% of patients took their medication regularly) with DOAC were high. Patients treated with DOAC in Spain have a high thromboembolic risk. A significant proportion of patients receive a lower dose of DOAC than that recommended according to their clinical profile. Satisfaction and medication adherence are high.Universitat Autònoma de Barcelona 22018-01-0120182018-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/287811https://dx.doi.org/urn:doi:10.1016/j.aprim.2017.05.009reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaEspañolspaopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.https://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2878112026-06-06T12:50:31Z
dc.title.none.fl_str_mv Clinical characteristics of patients with atrial fibrillation treated with direct oral anticoagulants attended in primary care setting
The SILVER-AP study
Perfil clínico de pacientes con fibrilación auricular tratados con anticoagulantes orales de acción directa atendidos en atención primaria
title Clinical characteristics of patients with atrial fibrillation treated with direct oral anticoagulants attended in primary care setting
spellingShingle Clinical characteristics of patients with atrial fibrillation treated with direct oral anticoagulants attended in primary care setting
de la Figuera, Mariano|||0000-0003-2533-2135
Anticoagulación
Anticoagulantes orales de acción directa
Anticoagulation
Atención primaria
Direct oral anticoagulants
Fibrilación auricular no valvular
Non-valvular atrial fibrillation
Primary care
title_short Clinical characteristics of patients with atrial fibrillation treated with direct oral anticoagulants attended in primary care setting
title_full Clinical characteristics of patients with atrial fibrillation treated with direct oral anticoagulants attended in primary care setting
title_fullStr Clinical characteristics of patients with atrial fibrillation treated with direct oral anticoagulants attended in primary care setting
title_full_unstemmed Clinical characteristics of patients with atrial fibrillation treated with direct oral anticoagulants attended in primary care setting
title_sort Clinical characteristics of patients with atrial fibrillation treated with direct oral anticoagulants attended in primary care setting
dc.creator.none.fl_str_mv de la Figuera, Mariano|||0000-0003-2533-2135
Cinza, Sergio
Marín, Nuria
Egocheaga, Isabel
Prieto, Miguel Angel
author de la Figuera, Mariano|||0000-0003-2533-2135
author_facet de la Figuera, Mariano|||0000-0003-2533-2135
Cinza, Sergio
Marín, Nuria
Egocheaga, Isabel
Prieto, Miguel Angel
author_role author
author2 Cinza, Sergio
Marín, Nuria
Egocheaga, Isabel
Prieto, Miguel Angel
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Anticoagulación
Anticoagulantes orales de acción directa
Anticoagulation
Atención primaria
Direct oral anticoagulants
Fibrilación auricular no valvular
Non-valvular atrial fibrillation
Primary care
topic Anticoagulación
Anticoagulantes orales de acción directa
Anticoagulation
Atención primaria
Direct oral anticoagulants
Fibrilación auricular no valvular
Non-valvular atrial fibrillation
Primary care
description To analyse the clinical characteristics and management of patients with non-valvular atrial fibrillation (NVAF) treated with direct oral anticoagulants (DOAC). Observational, cross-sectional and multicentre study. Autonomous Communities in which the general practitioner can prescribe DOAC (n = 9). The study included a total of 790 patients on chronic treatment with anticoagulants, and on whom therapy was changed, as well as being currently on treatment with DOAC for at least for 3 months. A record was made of the sociodemographic and clinical management date. Mean age was 78.6 ± 8.4 years, and 50.5% of patients were men. Mean CHADS score was 2.6 ± 1.2, mean CHADS-VASc score was 4.3 ± 1.6, and the mean HAS-BLED score was 2.3 ± 1.0. Mean duration of treatment with DOAC was 15.8 ± 12.5 months. Rivaroxaban was the DOAC most frequently prescribed (57.8%), followed by dabigatran (23.7%), and apixaban (18.5%). Of the patients receiving rivaroxaban, 70.2% were taking the dose of 20 mg/daily. Of the patients receiving dabigatran, 41.7% were taking the dose of 150 mg twice daily, and in the case of apixaban, 56.2% were taking the dose of 5 mg twice daily. Satisfaction (ACTS Burdens scale 52.0 ± 7.2 and ACTS Benefits scale 12.1 ± 2.2), and therapeutic adherence (97.8% of patients took their medication regularly) with DOAC were high. Patients treated with DOAC in Spain have a high thromboembolic risk. A significant proportion of patients receive a lower dose of DOAC than that recommended according to their clinical profile. Satisfaction and medication adherence are high.
publishDate 2018
dc.date.none.fl_str_mv 2
2018-01-01
2018
2018-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/287811
https://dx.doi.org/urn:doi:10.1016/j.aprim.2017.05.009
url https://ddd.uab.cat/record/287811
https://dx.doi.org/urn:doi:10.1016/j.aprim.2017.05.009
dc.language.none.fl_str_mv Español
spa
language_invalid_str_mv Español
language spa
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407682543222784
score 15,300719

Similares en LA Referencia